Cannapharmarx Stock Beta
CPMD Stock | USD 0.01 0.0002 2.50% |
CannaPharmaRx fundamentals help investors to digest information that contributes to CannaPharmaRx's financial success or failures. It also enables traders to predict the movement of CannaPharmaRx Pink Sheet. The fundamental analysis module provides a way to measure CannaPharmaRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CannaPharmaRx pink sheet.
CannaPharmaRx |
CannaPharmaRx Company Beta Analysis
CannaPharmaRx's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current CannaPharmaRx Beta | 0.21 |
Most of CannaPharmaRx's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CannaPharmaRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, CannaPharmaRx has a Beta of 0.2089. This is 75.71% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
CannaPharmaRx Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CannaPharmaRx's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CannaPharmaRx could also be used in its relative valuation, which is a method of valuing CannaPharmaRx by comparing valuation metrics of similar companies.CannaPharmaRx is currently under evaluation in beta category among its peers.
As returns on the market increase, CannaPharmaRx's returns are expected to increase less than the market. However, during the bear market, the loss of holding CannaPharmaRx is expected to be smaller as well.
CannaPharmaRx Fundamentals
Return On Equity | -2.51 | |||
Return On Asset | -0.26 | |||
Current Valuation | 20.13 M | |||
Shares Outstanding | 257.57 M | |||
Shares Owned By Insiders | 1.12 % | |||
Price To Book | 11.05 X | |||
EBITDA | (6.07 M) | |||
Net Income | (8.83 M) | |||
Cash And Equivalents | 5.18 K | |||
Total Debt | 14.96 M | |||
Debt To Equity | 7.05 % | |||
Book Value Per Share | (0.07) X | |||
Cash Flow From Operations | (2.41 M) | |||
Earnings Per Share | (0.12) X | |||
Beta | 0.21 | |||
Market Capitalization | 2.83 M | |||
Total Asset | 114.33 K | |||
Retained Earnings | (28.64 M) | |||
Working Capital | (285 K) | |||
Current Asset | 233 K | |||
Current Liabilities | 518 K | |||
Net Asset | 114.33 K |
About CannaPharmaRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CannaPharmaRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CannaPharmaRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CannaPharmaRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CannaPharmaRx Pink Sheet
CannaPharmaRx financial ratios help investors to determine whether CannaPharmaRx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CannaPharmaRx with respect to the benefits of owning CannaPharmaRx security.